Strong Results for Stroke Prevention Drugs at European Society of Cardiology Congress
BARCELONA, Aug 31 (Reuters) - AstraZeneca and Boehringer Ingelheim both unveiled strong results for new heart drugs at the European Society of Cardiology congress at the weekend -- but neither is guaranteed a home run with regulators.
Experts said questions remained about Boehringer's study design and a minor heart attack signal seen with its stroke prevention drug Pradaxa, while AstraZeneca's blood thinner Brilinta had failed to prove itself in North American patients.
Cardiologists meeting in Barcelona still gave both medicines good reviews, and both companies said the data would allow them to file their potential blockbusters with U.S. and European regulators by the year-end.
However, some doctors urged caution.
National Stroke Association’s mission is to reduce the incidence and impact of stroke by developing compelling education and programs focused on prevention, treatment, rehabilitation and support for all impacted by stroke.